TIMP-3 Antibody (183551) [Unconjugated]

VC001) or the HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the cytoplasm of tumor cells. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." > VC001) or the HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the cytoplasm of tumor cells. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." title="TIMP‑3 was detected in immersion fixed paraffin-embedded sections of human breast tumor using Mouse Anti-Human TIMP‑3 Monoclonal Antibody (Catalog # MAB973) at 5 µg/ml for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001) or the HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the cytoplasm of tumor cells. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." />

TIMP‑3 was detected in immersion fixed paraffin-embedded sections of human breast tumor using Mouse Anti-Human TIMP‑3 Monoclonal Antibody (Catalog # MAB973) at 5 µg/ml for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # <a class=

Abolishment of TGF-beta 1-mediated matrix remodeling by p38 and JNK inhibitors in the primary cultured orbital fibroblasts from patients with Graves’ ophthalmopathy (GO). (A) Orbital fibroblasts from GO patients were preincubated with the p38 inhibitor SB202190 (20 μM) and the JNK inhibitor SP600125 (20 μM), respectively, for 1 h, followed by TGF-beta 1 (5 ng/mL) treatment for another 24 h. Then, the expression levels of TIMP-1, TIMP-3, MMP-2, and MMP-9 were analyzed by Western blots; (B) The relative intensities of TIMP-1, TIMP-3, MMP-2, and MMP-9 expression normalized to each GAPDH control and DMSO control without TGF-beta 1 treatment were defined as 1.0. Then, the other relative intensity (folds) was presented. By three independent Western blot experiments, together data from the same patient strain were averaged. Then, the means of different patient (GO1–GO4, n = 4) strains were averaged; (C) The enzyme activities of MMP-2/-9 from the cultured medium were determined. The representative histogram was plotted based on the mean values of relative fluorescence units from the primary cultured orbital fibroblasts from the four GO patients. Data were presented as means ± S.D. of the results from three independent experiments. * p < 0.05 and ** p < 0.01 vs. control without TGF-beta 1 treatment; # p < 0.05 and ## p < 0.01 vs. TGF-beta 1 treatment. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/33799469), licensed under a CC-BY license. Not internally tested by R&D Systems.

973-TM) was serially diluted and captured by Mouse Anti-Human TIMP‑3 Monoclonal Antibody (Catalog # MAB973) coated on a Clear Polystyrene Microplate (Catalog # DY990). Mouse Anti-Human TIMP‑3 Monoclonal Antibody (Catalog # MAB9731) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" > 973-TM) was serially diluted and captured by Mouse Anti-Human TIMP‑3 Monoclonal Antibody (Catalog # MAB973) coated on a Clear Polystyrene Microplate (Catalog # DY990). Mouse Anti-Human TIMP‑3 Monoclonal Antibody (Catalog # MAB9731) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" title="Recombinant Human TIMP‑3 (Catalog # 973-TM) was serially diluted and captured by Mouse Anti-Human TIMP‑3 Monoclonal Antibody (Catalog # MAB973) coated on a Clear Polystyrene Microplate (Catalog # DY990). Mouse Anti-Human TIMP‑3 Monoclonal Antibody (Catalog # MAB9731) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" />

Recombinant Human TIMP‑3 (Catalog # <a class=

• Reactivity: Hu
• Applications: WB, IHC, IP, ELISA(Cap)
• Clone: 183551
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

TIMP-3 Antibody (183551) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human TIMP-3
  Cys24-Pro211
  Accession # P35625
• Specificity: Detects human TIMP-3 in ELISAs and Western blots. In Western blots, no cross-reactivity with recombinant human TIMP-1, -2, or -4 is observed.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: TIMP3
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.5-2.0 ug/mL
  • ELISA Standard (Matched Pair)
  • Immunohistochemistry 5-25 ug/mL
  • Immunoprecipitation 25 ug/mL
  • Western Blot 1 ug/mL
• Application Notes: ELISA Detection: Human TIMP-3 Biotinylated Antibody (Catalog number BAM9731)
  Standard: Recombinant Human TIMP-3 (Catalog number 973-TM)

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.
  *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TIMP-3 Antibody (183551) [Unconjugated]

• HSMRK222
• K222
• K222TA2
• metalloproteinase inhibitor 3
• MIG-5 protein
• Protein MIG-5
• pseudoinflammatory)
• SFD
• TIMP metallopeptidase inhibitor 3
• TIMP3
• TIMP-3
• tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy
• Tissue inhibitor of metalloproteinases 3

Background

Tissue inhibitors of metalloproteinases (TIMPs) are a family of proteins that regulate the activation and proteolytic activity of the zinc enzymes known as matrix metalloproteinases (MMPs). There are four members of the family, TIMP-1, TIMP-2, TIMP-3 and TIMP-4. TIMP-3 is a glycoprotein with a molecular mass of 30 kDa produced by a wide range of cell types. TIMP-3 inhibits active MMP-mediated proteolysis by forming a non-covalent binary complex with the MMP active site through its N-terminal domain. In addition, TIMP-3 is the only known member of the TIMP family that is an effective inhibitor of ADAMs such as TACE (1).

TIMP-3 is unique among the TIMPs because of its high affinity for binding to the extracellular matrix (2). Point mutations in the TIMP-3 C-terminal domain have been reported to result in Sorsby's fundus dystrophy, a disease leading to macular degeneration and loss of vision.

1. Amour, A. et al. (1998) FEBS Lett. 435:39.
2. Leco, K.J. et al. (1994) J. Biol. Chem. 269:9352.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for TIMP-3 Antibody (MAB973)(8)

Publications using MAB973

• Junker, F;Rupf, S;Schindler, PM;Wilden, C;Hohl, M;Ruiz-Gómez, G;Pisabarro, MT;Wrublewsky, S;Bickelmann, C;Berhorst, C;Alansary, D;Wieland, B;Bischoff, M;Lee, PS;Moeller, S;Berg, A;Dancker, TA;Lauterbach, MA;Ganse, B;Roma, LP;Steudter, T;Metzger, W;Tschernig, T;Ampofo, E;Laschke, MW;Hannig, M;Rother, S; Glycosaminoglycan-functionalized hydrogels for sustained delivery of tissue inhibitor of metalloproteinase-3 mediating matrix metalloprotease inhibition and extracellular matrix stabilization Bioactive materials 2026-07-01 [PMID: 41732672] (Immunohistochemistry)
• Varga, AJ;Nemeth, IB;Kemeny, L;Varga, J;Tiszlavicz, L;Kumar, D;Dodd, S;Simpson, AWM;Buknicz, T;Beynon, R;Simpson, D;Krenacs, T;Dockray, GJ;Varro, A; Elevated Serum Gastrin Is Associated with Melanoma Progression: Putative Role in Increased Migration and Invasion of Melanoma Cells International journal of molecular sciences 2023-11-28 [PMID: 38069171] (Western Blot, Human)
• Tonello, R;Silveira Prudente, A;Hoon Lee, S;Faith Cohen, C;Xie, W;Paranjpe, A;Roh, J;Park, CK;Chung, G;Strong, JA;Zhang, JM;Berta, T; Single-Cell Analysis of Dorsal Root Ganglia Reveals Metalloproteinase Signaling in Satellite Glial Cells and Pain Brain, behavior, and immunity 2023-08-07 [PMID: 37557960] (Immunohistochemistry, Western Blot, Human, Mouse)
• TY Hou, SB Wu, HC Kau, CC Tsai JNK and p38 Inhibitors Prevent Transforming Growth Factor-&amp;beta1-Induced Myofibroblast Transdifferentiation in Human Graves&#039; Orbital Fibroblasts International Journal of Molecular Sciences, 2021-03-14;22(6):. 2021-03-14 [PMID: 33799469] (Human)
• J Cassuto, A Folestad, J Göthlin, H Malchau, J Kärrholm Concerted actions by MMPs, ADAMTS and serine proteases during remodeling of the cartilage callus into bone during osseointegration of hip implants Bone Rep, 2020-09-11;13(0):100715. 2020-09-11 [PMID: 32995386] (ELISA Detection, Human)
• K Schubert, LE Collins, P Green, H Nagase, L Troeberg LRP1 Controls TNF Release via the TIMP-3/ADAM17 Axis in Endotoxin-Activated Macrophages J. Immunol., 2019-01-18;0(0):. 2019-01-18 [PMID: 30659107] (Neutralization, Human)
• Anastasios Chanalaris, Christine Doherty, Brian D. Marsden, Gabriel Bambridge, Stephen P. Wren, Hideaki Nagase et al. Suramin Inhibits Osteoarthritic Cartilage Degradation by Increasing Extracellular Levels of Chondroprotective Tissue Inhibitor of Metalloproteinases 3 Molecular Pharmacology 2017-10-01 [PMID: 28798097]
• Villeneuve J, Block A, Le Bousse-Kerdiles MC, Lepreux S, Nurden P, Ripoche J, Nurden AT Tissue inhibitors of matrix metalloproteinases in platelets and megakaryocytes: a novel organization for these secreted proteins. Exp. Hematol., 2009-05-03;37(7):849-56. 2009-05-03 [PMID: 19410025] (ICC, Human)

Bioinformatics

• Gene Symbol: TIMP3
• Uniprot:
  • P35625()